Watch how we identify the challenges, envision the solutions, and execute our mission of delivering precision, accessible cancer care through technology and global collaboration.
Today’s cancer treatments generate millions of genetic data points per patient—far beyond what traditional analysis can manage. As genetic data doubles every two years, outdated methods fail to keep up, leaving valuable insights untapped and delaying critical treatment decisions.
Genavinta’s advanced AI technology is designed to scale with the exponential growth of data. By processing vast datasets in minutes, our platform delivers actionable insights, ensuring that no data is left behind. This empowers doctors to make faster, more precise treatment decisions for their patients.
78% of genomic studies focus on European populations, while Asian populations represent only 10%, African 2%, and Hispanic 1%. This massive research gap means most cancer treatments are developed and tested primarily on European genetic profiles. We're changing this by actively analyzing diverse genetic data across populations, ensuring treatments work effectively for everyone, not just the historically overrepresented.
We're building the world's most diverse genetic database, partnering with hospitals across Asia, Africa, and beyond. Our AI analyzes this rich data to understand how treatments work across different populations. This means doctors can choose treatments proven effective for their specific patient groups, not just global averages
Cancer patterns vary dramatically between regions - breast cancer subtypes common in Southeast Asia are rare in Europe, while certain genetic markers critical for treatment choice appear at different rates across populations. Using global averages for local treatment decisions isn't just ineffective - it's potentially dangerous.
Our platform analyzes regional genetic patterns to guide local treatment decisions. Working with leading hospitals in each region, we've built genetic profiles that reflect local populations. Doctors get recommendations based on data from patients who share their community's genetic background, not just global statistics.
Our platform doesn’t just analyze genetic data—it combines pathology, medical history, and treatment outcomes. This creates a unified view of every patient’s cancer journey, helping doctors make informed decisions with confidence.
From individual treatment plans to large-scale clinical strategies,
our technology provides both granular and comprehensive insights. We bridge the gap between
patient-level care and system-level efficiency.
Our platform continuously updates disease models, ensuring your decisions
are based on the most current and comprehensive genetic data available.
Make clinical decisions faster and with greater precision.